Biopharma Business

Tag "anaplastic lymphoma kinase"

EMA’s CHMP backs Novartis’ Zykadia for first-line use in lung cancer

    EMA’s CHMP backs Novartis’ Zykadia for first-line use in lung cancer

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval to expand the use of Novartis’ Zykadia (ceritinib) in anaplastic lymphoma kinase (ALK)-positive non-small cell

Read Full Article

Upcoming Events

[eventlist]

The Magazine

New Subscriber

Subscribe Here



Advertisements